logo
Plus   Neg
Share
Email

AbbVie Seeks Approval For SKYRIZI For Treatment Of Adults With Psoriatic Arthritis

AbbVie (ABBV) has submitted applications seeking approval for SKYRIZI to the FDA and for SKYRIZI to the European Medicines Agency for the treatment of adults with active psoriatic arthritis. The submissions were supported by two pivotal phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2. The safety profile of SKYRIZI in these studies was generally consistent with the safety profile of SKYRIZI in plaque psoriasis.

SKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Nasdaq Inc. (NDAQ) reported Wednesday that its net income for the first quarter grew to $298 million or $1.78 per share from $203 million or $1.22 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $327 million or $1.96 per share, compared to $251 million... Guan's Mushroom Co. is recalling all cases of its 200g/7.05-ounce packages of Enoki Mushroom citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recalled Enoki is a product of China and comes in a clear plastic package with the description "Enoki Mushroom" in English, Korean and French, and Guan's logo in the front. Shares of Roche were gaining around 2 percent in Swiss trading after the drug major reported Wednesday a 3 percent rise in first-quarter sales at constant currency basis mainly driven by strong growth in Diagnostics Division. Sales, on a reported basis, edged down 1 percent mainly with significant impact from biosimilars. Looking ahead for fiscal 2021, the company continues to expect sales to grow
Follow RTT